Advanced Search

Show simple item record

dc.contributor.authorArtan, Ayse Serra
dc.contributor.authorMirioglu, Safak
dc.contributor.authorHocaoglu, Rabia Hacer
dc.contributor.authorTurgutalp, Kenan
dc.contributor.authorBoz, Saide Elif Gullulu
dc.contributor.authorEren, Necmi
dc.contributor.authorDincer, Mevlut Tamer
dc.date.accessioned2025-12-28T16:40:21Z
dc.date.available2025-12-28T16:40:21Z
dc.date.issued2024
dc.identifier.issn1471-2369
dc.identifier.urihttps://doi.org/10.1186/s12882-024-03784-8
dc.identifier.urihttps://hdl.handle.net/20.500.12933/2532
dc.description.abstractBackground We evaluated the efficacy of different immunosuppressive regimens in patients with primary membranous nephropathy in a large national cohort. Methods In this registry study, 558 patients from 47 centers who were treated with at least one immunosuppressive agent and had adequate follow-up data were included. Primary outcome was defined as complete (CR) or partial remission (PR). Secondary composite outcome was at least a 50% reduction in estimated glomerular filtration (eGFR), initiation of kidney replacement therapies, development of stage 5 chronic kidney disease, or death. Results Median age at diagnosis was 48 (IQR: 37-57) years, and 358 (64.2%) were male. Patients were followed for a median of 24 (IQR: 12-60) months. Calcineurin inhibitors (CNIs) with or without glucocorticoids were the most commonly used regimen (43.4%), followed by glucocorticoids and cyclophosphamide (GC-CYC) (39.6%), glucocorticoid monotherapy (25.8%), and rituximab (RTX) (9.1%). Overall remission rate was 66.1% (CR 26.7%, PR 39.4%), and 59 (10.6%) patients reached secondary composite outcome. Multivariate logistic regression showed that baseline eGFR (OR 1.011, 95% CI: 1.003-1.019, p = 0.007), serum albumin (OR 1.682, 95% CI: 1.269-2.231, p < 0.001), and use of RTX (OR 0.296, 95% CI: 0.157-0.557, p < 0.001) were associated with remission rates; whereas only lower baseline hemoglobin was significantly associated with secondary composite outcome (OR: 0.843, 95% CI: 0.715-0.993, p = 0.041). CYC use was significantly associated with higher remission (OR 1.534, 95% CI: 1.027-2.290, p = 0.036). Conclusions Higher baseline eGFR and serum albumin levels correlated with increased remission rates. Remission rates were lower in patients treated with RTX, while those on GC-CYC showed higher rates of remission. Due to the study's retrospective nature and multiple treatments used, caution is warranted in interpreting these findings.
dc.language.isoen
dc.publisherBmc
dc.relation.ispartofBmc Nephrology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectMembranous nephropathy
dc.subjectImmunosuppression
dc.subjectChronic kidney disease
dc.subjectRemission
dc.titleObservational study of immunosuppressive treatment patterns and outcomes in primary membranous nephropathy: a multicenter retrospective analysis
dc.typeArticle
dc.identifier.orcid0000-0002-3156-4883
dc.identifier.orcid0000-0003-0362-8154
dc.identifier.orcid0000-0001-6502-2399
dc.identifier.orcid0000-0003-2467-9356
dc.identifier.orcid0000-0001-5943-0302
dc.identifier.orcid0000-0002-0409-2710
dc.identifier.orcid0000-0002-6461-3178
dc.departmentAfyonkarahisar Sağlık Bilimleri Üniversitesi
dc.identifier.doi10.1186/s12882-024-03784-8
dc.identifier.volume25
dc.identifier.issue1
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.department-temp[Artan, Ayse Serra; Hocaoglu, Rabia Hacer; Yazici, Halil; Ozturk, Savas] Istanbul Univ Istanbul, Fac Med, Dept Internal Med, Div Nephrol, Istanbul, Turkiye; [Mirioglu, Safak; Elcioglu, Omer Celal] Bezmialem Vakif Univ, Fac Med, Dept Internal Med, Div Nephrol, Istanbul, Turkiye; [Turgutalp, Kenan] Mersin Univ, Dept Internal Med, Sch Med, Div Nephrol, Mersin, Turkiye; [Boz, Saide Elif Gullulu] Uludag Univ, Dept Internal Med, Med Fac, Div Nephrol, Bursa, Turkiye; [Eren, Necmi] Kocaeli Univ, Med Fac, Dept Internal Med, Div Nephrol, Kocaeli, Turkiye; [Dincer, Mevlut Tamer] Istanbul Univ, Cerrahpasa Cerrahpasa Med Fac, Dept Internal Med, Div Nephrol, Istanbul, Turkiye; [Uzun, Sami] Univ Hlth Sci, Haseki Training & Res Hosp, Div Nephrol, Istanbul, Turkiye; [Sahin, Gulizar] Univ Hlth Sci S Abdulhamid Res, Training Hosp, Div Nephrol, Istanbul, Turkiye; [Kutlay, Sim] Ankara Univ, Fac Med, Dept Internal Med, Div Nephrol, Ankara, Turkiye; [Cevher, Simal Koksal] Ankara City Hosp, Div Nephrol, Ankara, Turkiye; [Dheir, Hamad] Sakarya Univ, Fac Med, Dept Internal Med, Div Nephrol, Sakarya, Turkiye; [Yilmaz, Murvet] Bakirkoy Sadi Konuk Training & Res Hosp, Div Nephrol, Istanbul, Turkiye; [Basturk, Taner] Univ Hlth Sci, Hamidiye Etfal Training & Re
dc.identifier.pmid39354386
dc.identifier.scopus2-s2.0-85205527502
dc.identifier.scopusqualityQ2
dc.identifier.wosWOS:001326720700004
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.snmzKA_WoS_20251227


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record